
NASDAQHealthcareBiotechnology
最新資料
US$1.52
−US$0.135 · -8.16%
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
前收盤價
US$1.52
−US$0.135 · -8.16%
盤中時間採用ET。市場資料可能有所延遲。
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
日內區間
目前US$1.52
52週區間
目前US$1.52
盤中時間採用ET。市場資料可能有所延遲。
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
日內區間
目前US$1.52
52週區間
目前US$1.52
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(AUD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 543.89萬 AUD | 401.93萬 AUD | 391.63萬 AUD | 512.35萬 AUD |
| 銷貨成本 | 11.3萬 AUD | 12.75萬 AUD | 21.43萬 AUD | 28.51萬 AUD | 36.47萬 AUD |
| 毛利 | −11.3萬 AUD | 531.14萬 AUD | 380.5萬 AUD | 363.13萬 AUD | 475.89萬 AUD |
| 研究與開發 | 1724.43萬 AUD | 1440.43萬 AUD | 1864.4萬 AUD | 1319.86萬 AUD | 1474.58萬 AUD |
| 銷售、一般及管理費用 | 1044.2萬 AUD | 548.14萬 AUD | 476.26萬 AUD | 503.94萬 AUD | 551.39萬 AUD |
| 營業費用 | 2768.63萬 AUD | 1988.57萬 AUD | 2340.67萬 AUD | 1823.8萬 AUD | 2025.97萬 AUD |
| 利息收入 | 167.91萬 AUD | 44.63萬 AUD | 26.84萬 AUD | 1.64萬 AUD | 2504 AUD |
| 折舊和攤銷 | 11.3萬 AUD | 13.97萬 AUD | 14.75萬 AUD | 10.23萬 AUD | 5.42萬 AUD |
| 營業利益 | −2779.93萬 AUD | −1457.43萬 AUD | −1960.17萬 AUD | −1463.61萬 AUD | −1550.2萬 AUD |
| 淨利 | −2288.96萬 AUD | −1214.78萬 AUD | −1912.35萬 AUD | −1380.65萬 AUD | −1284.71萬 AUD |
公司資料更新於 2026年11月22日。
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$8.00
上漲空間 426.32%AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。